In order to assess whether combined treatment of ABT-263 and idasanutlin could have a broad therapeutic applicability in neuroblastoma, we evaluated both compounds in 10 human neuroblastoma cell lines with varying MCL1 and BCL2 expression levels. This evidence concerns the gene BCL2 and neuroblastoma.